This study examined drug interactions between buprenorphine, an opioid partial agonist medication used in the treatment of opioid dependence, and the nonnucleoside reverse-transcriptase inhibitors (NNRTIs) efavirenz (EFV) and delavirdine (DLV). Opioid-dependent, buprenorphine/naloxone-maintained, human immunodeficiency virus (HIV)-negative volunteers ( per NNRTI) participated in 24-h sessions to determine pharn p 10 macokinetics of buprenorphine and of buprenorphine with either EFV or DLV after administration of standard doses of either antiretroviral for 15 or 7 days, respectively. Opiate withdrawal symptoms, cognitive effects, and adverse events were determined before and after antiretroviral administration in opioid-dependent participants. The pharmacokinetics of NNRTIs in healthy control participants were used to determine the effect of buprenorphine on NNRTIs. EFV decreased the buprenorphine area under the concentration-time curve ( ). DLV increased buprenorphine concentrations ( ). Clinically significant consequences of these P ! .001 P ! .001 interactions were not observed. Buprenorphine did not alter antiretroviral pharmacokinetics. Adjustments of doses of either buprenorphine or EFV or DLV are not likely to be necessary when these drugs are administered for the treatment of opiate dependence and HIV disease.
supratherapeutic concentrations of these medications, which may influence the effectiveness of both treatment strategies [1] .
During the past few years, major advances in HIV therapeutics have resulted from new insights into viral pathogenesis, the availability of viral load measurements, and, most important, the advent of potent combination antiretroviral agents. These advances have led to dramatic effects on virologic and immunologic outcomes and have also provided clear clinical benefits [2] . However, special limitations to some of these therapies in individuals receiving methadone maintenance therapy have been identified, including adverse drug interactions and/or toxicities [1, 3] .
Buprenorphine, a m-opioid receptor partial agonist, has demonstrated efficacy in the treatment of opioiddependent patients [4] . Like other m-opioid agonists, buprenorphine produces typical opioid-associated subjective and physiological effects, but its maximal effects are less than those of a full agonist, such as morphine [5] . With escalating doses, buprenorphine produces less subjective effect and less effect on respiration than do full m-opioid agonists and exhibits a ceiling effect to these properties, at which further dose increases produce no additional effects [5] . Buprenorphine has been shown to be equivalent to moderate doses of methadone in the treatment of opioid-dependent patients [4] . It is marketed as a sublingual formulation of buprenorphine/naloxone (4:1; Suboxone; Reckitt Benckiser) for maintenance pharmacotherapy for opioid-dependent individuals. Naloxone is poorly absorbed by the sublingual route and does not alter the opioid effects of buprenorphine. However, the presence of naloxone in the buprenorphine/naloxone tablet discourages diversion to injection abuse by opioid-dependent individuals, because the opioid antagonist effects of naloxone predominate if the combination drug is solubilized and injected [4] . This formulation is attractive as a treatment for opioid dependence and, unlike methadone, is available by prescription from qualifying physicians [4] .
Methadone has shown troubling interactions with antiretroviral agents of several classes [1, 3] . Because it is cleared primarily through conversion to an inactive metabolite by cytochrome P450 (CYP) enzymes, principally CYP3A4 and CYP2B6 [6] , methadone is particularly susceptible to the induction or inhibition of these enzymes by certain antiretroviral drugs. Buprenorphine may be less susceptible to such effects. It is principally converted by CYP3A4 and CYP2C8 to the active metabolite, norbuprenorphine [7] . Conversion to an active metabolite could blunt the effect of enzyme induction. Buprenorphine is also cleared by glucuronidation, as is norbuprenorphine [8] . The availability of an alternate route of clearance, along with a ceiling effect at higher concentrations, could reduce the effects of CYP inhibition.
The nonnucleoside reverse-transcriptase inhibitors (NNRTIs) are an important class of antiretroviral medications that are frequent components of HAART regimens. This class of antiretrovirals has previously been shown to have important pharmacokinetic interactions with methadone. Among these, efavirenz (EFV), the most frequently prescribed medication in the class, is a potent inducer of CYP3A4 that has been shown to precipitate opiate withdrawal when administered with methadone [1] , whereas delavirdine (DLV) is a known inhibitor of CYP3A4 that increases concentrations of methadone [9] . The goals of the present study included the following: (1) to determine whether the pharmacokinetics of the opioid dependence medication buprenorphine (administered in this study as the buprenorphine/naloxone combination tablet that is used in the clinical setting for the treatment of opioid dependence) are affected by coadministration of either of the NNRTI medications EFV or DLV; (2) to determine whether the pharmacokinetics of these NNRTIs are affected by coadministration of buprenorphine; and (3) to determine whether clinically significant pharmacodynamic effects or toxicities occur when buprenorphine is administered simultaneously with either NNRTI. Answers to these questions could make a significant contribution to optimizing clinical care for HIV-infected, opioid-dependent patients.
METHODS

Procedures.
The general design of this study has been reported elsewhere [9, 10] . Thirty-five individuals participated, including 10 opioid-dependent individuals who had been stable for at least 2 weeks while receiving a daily dose of sublingual buprenorphine/ naloxone of between 16/4 and 20/5 mg and who participated in a 24-h blood and urine sampling study to determine buprenorphine pharmacokinetics followed by administration of either EFV (600 mg daily) for 15 days or DLV (600 mg twice daily) for 7 days, as well as a second 24-h pharmacokinetic study in which blood and urine sampling for buprenorphine and antiretroviral plasma concentrations was performed. Fifteen age-, weight-, race-, and sex-matched control volunteers participated in the DLV pharmacokinetic study, in which they received DLV (600 mg twice daily) for 7 days, followed by a 24-h blood and urine sampling study to determine DLV pharmacokinetics. The 15-day duration of efavirenz dosing was based on the maximum induction of CYP3A4 by 11 days after administration [11] plus the 4 days required for maximum symptoms to develop after buprenorphine withdrawal [12] . Inhibition of CYP enzymes by DLV was assumed to be a direct effect requiring no induction. Under this assumption, 7 days would be sufficient for both DLV and buprenorphine to accumulate to steady-state levels. A control sample was not obtained for the EFV study, because of the significant rate of neurological adverse effects (altered mental status, memory problems, dizziness, and incoordination) reported for this medication. Instead, data on maximum concentration in plasma (C max ) and minimum concentration in plasma (C min ) available in the published literature [13] were used to estimate the effect of buprenorphine on EFV disposition.
Study procedures included standardized and validated measurement of opiate withdrawal by clinician rating (Objective Opiate Withdrawal Scale, on which scores у3 indicate moderate withdrawal symptoms) [14] and of cognitive impairment by use of the Mini-Mental State Examination [15] for opioiddependent participants (maximum score, 30; scores !27 indicate cognitive impairment). Adverse symptoms were recorded for all participants, using an Adverse Symptoms Checklist that queried for a wide range of adverse experiences, including changes in energy, gastrointestinal symptoms, CNS effects, genitourinary symptoms, and other somatic complaints, scored for severity on an ordinal scale (0, not present; 1, mild; 2, moderate; 3, severe [maximum possible total score, 87]). These ratings were evaluated at baseline, after stabilization with buprenorphine (before antiretroviral administration), and at completion of the NNRTI dosing period, for control participants before and at completion of NNRTI administration.
Biochemical assays. Buprenorphine and metabolite concentrations were determined using a recently described liquid chromatography-tandem mass spectrometry method [16] . In brief, buprenorphine-d 4 , norbuprenorphine-d 3 and morphine-3-b-d-glucuronide-d 3 were added to samples as the internal standards. The pH of the matrix was adjusted to 9.3 with ammonium carbonate buffer, and samples were extracted using C18 solid-phase extraction columns. The eluate was evaporated and reconstituted with 0.1% formic acid in water and was analyzed by liquid chromatography-tandem mass spectrometry using electrospray ionization.
Plasma samples for the quantification of EFV were assayed by use of a previously published high-performance liquid chromatography method [17] . Plasma samples for quantification of DLV were assayed by a validated isocratic high-performance liquid chromatography method, as described elsewhere [18] .
Pharmacokinetic analysis. The pharmacokinetic parameters of buprenorphine, norbuprenorphine, buprenorphine-3-glucuronide, norbuprenorphine-3-glucuronide, EFV, and DLV were evaluated as appropriate for each participant. Buprenorphine pharmacokinetics were calculated after sublingual administration of buprenorphine/naloxone alone and again after administration of either EFV or DLV. In the control group, DLV pharmacokinetic parameters were evaluated after administration as described above. The 24-h area under the concentration-time curve (AUC 0-24 ), C min , C max , the time of C max (T max ), and the sublingual (buprenorphine) or oral (DLV) clearance (Cl/F) were determined using the noncompartmental analysis module of WinNonLin Professional software, version 3.2 (Pharsight). For metabolites, Cl/F was calculated on the basis of the administered dose of parent compound. The F term thereby represents the fraction of parent drug ultimately converted to the metabolite. C max , C min , and T max were estimated by inspection of the raw data. For purposes of noncompartmental analysis, drug concentrations that were lower than the limit of quantitation were expressed as one-half of the limit. All pharmacokinetic parameters were summarized and displayed by treatment period. Urine results were calculated as a percentage of the daily dose, with a molar conversion for metabolites: % of daily dose p (amount) (molecular weight of buprenorphine) (molecular weight of metabolite)
Ϫ1
(daily dose)
. Renal clearance was determined as follows: (amount in urine) (AUC 0-24 )
. Statistical analysis. Previous experience with drug interaction studies examining methadone in combination with antiretroviral medications indicated that the between-subject coefficient of variation for the AUC 0-24 would be ∼30%. It was also assumed that a у40% change in the AUC 0-24 would be of clinical importance, as we observed in our study of lopinavir/ritonavir and methadone and in our study of zidovudine and methadone [19] . A sample size of 10 is needed to detect, with a power of 0.8, a 40% change in the antiretroviral drug AUC 0-24 or the oral clearance between control and buprenorphine-treated participants. The studies of NNRTI effects on buprenorphine, on the other hand, were within subject. Withinsubject coefficients of variation are smaller, and the design has more statistical power. A sample size of 7 was adequate to detect a difference of 40% in the AUC 0-24 between buprenorphine alone and buprenorphine in combination with an antiretroviral agent [20] . Student's paired t test was used to test the significance of the differences in pharmacokinetic parameters for buprenorphine alone and in combination (within-subject analyses). The Wilcoxon test was used for the within-subject comparison of the values of T max . Differences in pharmacokinetic parameters for DLV in the control group versus the buprenorphine-treated group (between-group comparisons) were obtained by use of the Kruskal-Wallis test or the Mann-Whitney test (for T max ). A difference was considered to be statistically significant if the P value was р.05 (2-tailed). Comparisons of participant characteristics were made by single-factor analysis of variance.
RESULTS
Study Participants
A total of 35 individuals participated in this study. Twenty opioid-dependent participants receiving a stable, daily, sublingual dose of buprenorphine/naloxone (dose range, 16/4 to 20/ 5 mg) who were otherwise physically healthy and without current psychiatric illness completed the study. Fifteen control participants who were matched for age, race, sex, and weight to the opioid-dependent participants completed pharmacokinetic studies for DLV. Table 1 shows the demographic and clinical characteristics of study participants, according to the medication regimen studied. There were no significant differences in age, race, weight, or sex. Opioid-dependent participants received a stable dose of buprenorphine/naloxone for at least 2 weeks before study entry. On the basis of clinical assessment, the condition of most participants was stabilized (defined as a lack of opiate withdrawal symptoms and cessation of opiate craving and use [as determined by urine toxicology screen]) with 16/4 mg of buprenorphine/naloxone daily; 3 participants required 20/5 mg of buprenorphine/naloxone daily for stabilization. Few adverse events occurred during the study period, and no medical intervention was required to address adverse events in any participant during the course of the study. Concomitant medication use in this sample was rare. One buprenorphine/naloxone-maintained participant in the EFV study component was treated with hydrochlorothiazide for hypertension. The abuse of substances other than opioids was a common occurrence, in both the buprenorphine/naloxone and control groups, with cocaine abuse most prevalent, followed by cannabis abuse (in opioid-dependent participants) and alcohol abuse (no participants met diagnostic criteria for alcohol dependence). Cigarette smoking was common, but daily use reported by all participants was !1 pack/day (range, 0.3-0.6 pack/day). Injection drug use was common among the opioiddependent participants (range, 30%-40%), although nasal insufflation was the preferred route of administration for most participants. Serological evidence of hepatitis C virus infection was common among opioid-dependent participants (30%-40% for each antiretroviral study group).
Interaction between Buprenorphine and NNRTIs
Effect of EFV on buprenorphine. Pharmacokinetic parameters for buprenorphine and metabolites before and after EFV administration are shown in table 2. Figure 1 graphically represents the mean concentrations of buprenorphine; the active metabolite, norbuprenorphine; and the inactive glucuronides of buprenorphine and norbuprenorphine over a 24-h dosing interval. Of note, individual buprenorphine profiles usually exhibited secondary peaks, consistent with enterohepatic recirculation. The secondary peaks occurred at times varying among individuals from 6 to 10 h. Because of averaging, this effect is only modestly apparent in figure 1A , which plots the mean concentration for all participants at each time point. The coadministration of EFV with buprenorphine significantly decreased the buprenorphine AUC 0-24 , by ∼50% (AUC 0-24 : before EFV administration, 40.3 ng7h/mL; after EFV administration, 20.6 ng7h/mL; ) P ! .001 (table 2) . Similarly, the norbuprenorphine AUC 0-24 was reduced by 71% ( ). Corresponding increases in the Cl/F for bu-P ! .001 prenorphine (
) and norbuprenorphine ( ) were P p .002 P p .011 
NOTE.
Data are for 10 participants who participated in both mean ‫ע‬ SE sessions, with the exception of time of maximum concentration (T max ), for which data are median (range). Student's paired t test was used to determine P values for all parameters except T max , for which the Wilcoxon test was used. AUC 0-24 , 24-h area under the concentration-time curve; C max , maximum concentration in plasma; C min , minimum concentration in plasma; Cl/F, clearance; NS, not significant. observed (table 2) . C max and C min decreased for both buprenorphine ( and , respectively) and norbuprenor-P p .001 P ! .001 phine ( and , respectively) after EFV adminis-P p .026 P ! .001 tration. T max for buprenorphine increased nonsignificantly after EFV administration (P p .054). An analysis of the glucuronide metabolites of buprenorphine and norbuprenorphine showed that, although there was a nonsignificant decrease in the buprenorphine glucuronide AUC 0-24 after EFV administration, the Cl/F for this metabolite was significantly increased ( ) P p .012 (table 2) . When the results were reanalyzed after excluding outlier data from 1 participant with extremely high buprenorphine glucuronide concentrations both before and after EFV administration, the percentage decrease in the AUC 0-24 became substantial and statistically significant (mean : before EFV ad-AUC ‫ע‬ SE 0-24 ministration, 28.1 ‫ע‬ 3.0 ng7h/mL; after EFV administration, 11.5 ‫ע‬ 3.1 ng7h/mL;
). The norbuprenorphine glucu-P p .002 ronide AUC 0-24 decreased significantly ( ), and the Cl/F P p .006 increased ( ). P p .027
The amounts of buprenorphine and metabolites were also measured in urine collected over the 24-h dosing intervals of the pharmacokinetic studies and were used to calculate renal clearance. There were no significant differences between any of the renal clearance values obtained before and after administration. The amounts of buprenorphine and its metabolites found in the urine were reduced after EFV administration. In general, the ratios to the pretreatment amounts approximated the ratios of the AUC 0-24 values (data not shown).
Despite significant decreases in exposure to buprenorphine and norbuprenorphine with EFV coadministration, no participants showed evidence of opiate withdrawal symptoms (mean Objective Opiate Withdrawal Scale : before EFV adscore ‫ע‬ SE ministration, ; after EFV administration, ; dif-0 ‫ע‬ 0 0 . 1 ‫ע‬ 0.1 ference not significant), nor were cognitive deficits detected (mean Mini-Mental State Examination : before EFV score ‫ע‬ SE administration, ; after EFV administration, 28.6 ‫ע‬ 0. 5 28.8 ‫ע‬ ). EFV administration had no significant effect on hepatic 0.3 enzyme activity (aspartate aminotransferase or alanine aminotransferase). The most frequently reported adverse symptoms in buprenorphine/naloxone-maintained individuals administered EFV were constipation, drowsiness, dry mouth, and frequent urination, all of which decreased with EFV administration. The only symptoms that increased with EFV administration for several participants were nightmares (before EFV administration, 0 participants reported nightmares; after EFV administration, 3 participants reported nightmares, with 2 rating this adverse symptom as "mild" and 1 rating this adverse symptom as "moderate") and waking up during the night (before EFV administration, 3 participants reported this symptom as "mild"; after EFV administration, 1 participant reported this adverse symptom to be "mild," 2 reported it to be "moderate," and 1 reported it to be "severe"). There were no statistically significant changes in adverse symptoms before and after EFV administration in this sample.
Effect of DLV on buprenorphine. DLV administration to buprenorphine/naloxone-maintained study participants was associated with a 14-fold increase in the AUC 0-24 ( ) (figure P ! .001 2A and table 3). Correspondingly, the Cl/F for buprenorphine significantly decreased ( ), and the C max increased, P ! .001 from 6.2 to 21.3 ng/mL ( ) ( figure 2A and table 3) . The P ! .001 AUC 0-24 of norbuprenorphine was significantly decreased (P p ) (figure 2B), Cl/F was significantly increased ( ), .002 P p .002 and the C max was decreased ( ) (table 3) . Despite a 4-P p .004 fold increase in the mean AUC 0-24 of buprenorphine glucuronide, this change was not statistically significant, because of very high SEs in both groups. As was also the case with EFV, reanalysis after exclusion of 1 participant with very high AUC 0-24 values, both before and after DLV administration, substantiallydecreased the SEs and resulted in significant differences between the buprenorphine AUC 0-24 values (mean AUC 0-24 ‫ע‬ SE: before DLV administration, ng7h/mL; after DLV administration, 29.2 ‫ע‬ 8.0 ng7h/mL; P p .026). Consistent with the reduced 82.0 ‫ע‬ 20.0 norbuprenorphine exposure, the norbuprenorphine glucuronide AUC 0-24 was significantly reduced ( ) ( figure 2D and table P ! .001 3). After DLV administration, the Cl/F for norbuprenorphine glucuronide increased ( ), and the T max decreased (P P p .002 p .020) (table 3). As was true for EFV, renal clearance of buprenorphine and its metabolites was not significantly affected, and changes in urinary recovery paralleled changes in AUC 0-24 values. The increase in the percentage of the dose reaching the urine as buprenorphine glucuronide was highly significant, confirming the increased clearance of buprenorphine by direct glucuronidation (data not shown).
DLV administration to buprenorphine/naloxone-maintained study participants was not associated with opiate withdrawal symptoms (mean Objective Opiate Withdrawal Scale score: before DLV administration, 0; after DLV administration, 0) or impaired cognition (mean Mini-Mental State Examination : before DLV administration, ; after DLV score ‫ע‬ SE 29.2 ‫ע‬ 0.3 administration, ). DLV administration had no sig-29.4 ‫ע‬ 0.2 nificant effect on hepatic enzyme activity (aspartate aminotransferase or alanine aminotransferase) in buprenorphine/ naloxone-maintained participants, although it resulted in a statistically significant but clinically inconsequential decrease in the alanine aminotransferase concentration in control participants ( ) (table 1) . Adverse symptoms were infrequently P p .01 reported for buprenorphine/naloxone-maintained individuals administered DLV. Drowsiness was the only adverse symptom reported that significantly increased with DLV administration ( ). Few adverse symptoms were reported by control P p .03 participants before or after DLV administration. The only adverse symptom for which a significant change was observed was that of muscle stiffness, which significantly decreased with DLV administration ( ). P p .04 Effect of buprenorphine on EFV and DLV. Over a 24-h dosing interval, EFV concentrations were measured in buprenorphine/naloxone-maintained individuals ( figure 3A) . The mean EFV concentrations (‫ע‬SE) did not differ significantly from values observed among healthy, non-opioid-dependent, historical control individuals [13] (C max [EFV plus buprenorphine], 14.0 mmol/L). 5.6 ‫ע‬ 3.2 Buprenorphine/naloxone administration had no effect on the disposition of DLV, except for a modest delay in absorption, as reflected in a longer T max ( ) ( figure 3B and table 4) . P p .013 The disposition of the N-desalkyldelavirdine metabolite was likewise unaffected (data not shown). The ranges of plasma DLV concentrations at 12 h after the dose was administered were considerable: 5.52-45.1 mmol/L in the control group and 4.88-85.5 mmol/L in the buprenorphine/naloxone group.
DISCUSSION
The findings of the present study indicate that significant pharmacokinetic drug interactions occur when buprenorphine is administered simultaneously with the NNRTI inhibitors EFV and DLV. EFV produced a 49% decrease in the buprenorphine AUC 0-24 , as well as a 71% decrease in the AUC 0-24 for the active metabolite, norbuprenorphine. DLV produced a 325% increase in the buprenorphine AUC 0-24 but a 61% decrease in the norbuprenorphine AUC 0-24 . The net effect produced by DLV was an 87% increase in exposure to buprenorphine plus norbuprenorphine. Despite the magnitude of the changes in buprenorphine and norbuprenorphine exposure, no significant pharmacodynamic effects were detected, as measured by standardized scales for opiate withdrawal symptoms and cognition or by reports of adverse symptoms associated with concomitant administration of these medications.
Buprenorphine/naloxone is the US Food and Drug Administration-approved formulation of buprenorphine for the treatment of opioid dependence [4] . The combination with naloxone (4:1) was formulated to decrease diversion [4] . The Food and Drug Administration-approved combination tablet was used in the present study. Because of the minimal systemic availability of naloxone by the sublingual route, the findings of this study should be readily generalizable to treatment with buprenorphine alone (which is widely available for treatment outside of the United States). T max , h 2.0 (0.5-8.0) 0.875 (0.5-4.0) .020
NOTE. Data are for 10 participants who participated in both mean ‫ע‬ SE sessions, with the exception of time of maximum concentration (T max ), for which data are median (range). Student's paired t test was used to determine P values for all parameters except T max , for which the Wilcoxon test was used. AUC 0-24 , 24-h area under the concentration-time curve; C max , maximum concentration in plasma; C min , minimum concentration in plasma; Cl/F, clearance; NS, not significant.
Figure 3. Effect of buprenorphine on efavirenz (A) and delavirdine (B)
EFV is a potent inducer of CYP3A hepatic enzymes [11] , and chronic administration can produce more rapid metabolism of drugs that are CYP3A substrates, such as buprenorphine [7, 21] . The substantial and significant decrease in the AUC 0-24 , increase in the Cl/F, and decrease in the C max observed for buprenorphine are consistent with the induction of the CYP3A enzyme system by EFV. All of these observed changes could result either from an increase in clearance (Cl) or a decrease in bioavailability (F). Induction of CYP3A enzymes would be expected to increase buprenorphine clearance, but it would not be expected to have a substantial effect on bioavailability by the sublingual route. On the other hand, the observation of apparent enterohepatic recirculation suggests that buprenorphine can be absorbed from the intestine, such that any sublingually administered buprenorphine that is swallowed will be at least partially absorbed. Induction of CYP3A could reduce the bioavailability of buprenorphine reaching the system by this route. The observation of decreases in urinary recovery of buprenorphine and all of its metabolites, combined with a lack of decreases in intrinsic renal clearance, is consistent with an overall decrease in buprenorphine bioavailability. These findings suggest that EFV both increases clearance and decreases bioavailability of buprenorphine.
Inducers of CYP activity may also be inducers of glucuronidation, thus coupling phase I and phase II clearance routes [22] . The data presented here are consistent with induction of buprenorphine glucuronidation, in addition to N-dealkylation. With isolated induction of CYP3A enzymes, an increase in the fraction of buprenorphine converted to norbuprenorphine and norbuprenorphine glucuronide, relative to the fraction converted to buprenorphine glucuronide, would be expected. However, the mean fraction of buprenorphine glucuronide in the urinary buprenorphine metabolites (‫ע‬SE) changed only from 13.1% ‫ע‬ before EFV administration to after admin-5.1%
12.0% ‫ע‬ 5.4% istration (data not shown), consistent with roughly parallel increases in both pathways for buprenorphine metabolism.
Buprenorphine and norbuprenorphine at concentrations 10.7 ng/mL in plasma are associated with suppression of with- drawal symptoms [23] . Before administration of EFV, buprenorphine and norbuprenorphine concentrations in plasma were consistently higher than this level ( figure 1A and 1B) . However, after 15 days of EFV administration, buprenorphine and norbuprenorphine concentrations were reduced, such that the mean trough concentrations (‫ע‬SE) observed were 0.42 ‫ע‬ 0.10 and ng/mL, respectively. Despite this substantial 0.55 ‫ע‬ 0.15 decrease in buprenorphine exposure, no participant experienced opiate withdrawal symptoms, nor did any participant require an increase in buprenorphine/naloxone dose. Furthermore, urine drug screens revealed that participants were not using illicit opioids during this period. The explanation for this finding is not obvious, although the assertion that therapeutic concentrations in plasma (i.e., those above which opiate withdrawal symptoms are not present) are у0.7 ng/mL was based on findings in a relatively small sample of 11 men who participated in a study in which they knew that they would be completely withdrawn from buprenorphine treatment. The psychological effect of this knowledge could have contributed to the symptoms experienced. In the present study, participants were told that the effect of the antiretroviral medication on buprenorphine was unknown but could be associated with an increase, decrease, or no change in buprenorphine concentrations. Another possibility is that, because buprenorphine administration was not discontinued, the combined levels of buprenorphine and norbuprenorphine were sufficient to prevent the onset of withdrawal symptoms. It is also possible that the high affinity and slow dissociation of buprenorphine at mopioid receptors [5, 24] inhibits the development of opiate withdrawal symptoms in the face of decreasing or fluctuating concentrations of the drug in plasma.
These findings with buprenorphine are in contrast to methadone, for which opioid responses, including subjective effects and withdrawal symptoms, have been shown to correlate with methadone plasma concentrations, and small decreases in concentrations can result in significant withdrawal symptoms [25] . This might underlie the development of the significant withdrawal effects observed when therapy with some antiretroviral medications, such as nevirapine, EFV, or lopinavir/ritonavir [1] , is initiated in methadone-maintained patients. The lack of EFVinduced opiate withdrawal symptoms in buprenorphine/naloxone-treated individuals, compared with those in methadonetreated individuals, could also be related to the fact that the principal metabolite of buprenorphine (norbuprenorphine) is an agonist at m-opioid receptors [26] , whereas the metabolites of methadone have no m-opioid receptor activity [6] . This could result in a more significant decrease in opioid exposure in methadone-maintained individuals, relative to that noted in individuals treated with buprenorphine. Although the 15-day study period was longer than that necessary to produce steadystate EFV concentrations (the time to steady-state plasma concentrations of EFV is 6-10 days) [13] and should have been sufficient to allow for re-equilibration at the lower plasma concentrations of buprenorphine resulting from EFV exposure, it is possible that some might experience opiate withdrawal symptoms with long-term EFV therapy. In another study, no evidence for adverse effects of buprenorphine treatment on HIV treatment outcomes (viral load) was observed in the French Cohort Study of HIV-infected injection drug users (MANIF 2000) , although the number of buprenorphine-treated patients in this study was small ( ) [27] . n p 20 DLV is a potent inhibitor of CYP3A enzyme activity and would be expected to produce increases in plasma concentrations of drugs that are substrates of this enzyme system [28] . Administration of DLV at standard clinical dosages for 7 days to buprenorphine/naloxone-maintained individuals was associated with large increases in buprenorphine exposure, and norbuprenorphine concentrations were significantly diminished relative to baseline, because of the inhibition of CYP3A-mediated conversion of buprenorphine to norbuprenorphine [7, 21] . Consistent with the inhibition of buprenorphine metabolism via CYP3A, there were large increases in the mean buprenorphine glucuronide AUC 0-24 and in the percentage of urinary buprenorphine metabolites accounted for by buprenorphine glucuronide, indicating that glucuronidation becomes the predominant pathway for buprenorphine clearance when CYP3A enzymes are inhibited.
No opioid-associated subjective effects were elicited from buprenorphine/naloxone-maintained participants after DLV administration (e.g., no increase in constipation, drowsiness, or trouble concentrating was reported on the Adverse Symptoms Checklist). No mental status changes were observed, and results of formal cognitive testing with the Mini-Mental State Examination [15] were unchanged. One possible explanation for the lack of opioid toxicity despite the large increases in buprenorphine exposure is that buprenorphine is a partial agonist at the m-opioid receptor and has a ceiling to its opioid-associated responses [5] . Another factor that might mitigate against opioid toxicity is the observed decrease in exposure to the active metabolite, norbuprenorphine. A reduction in this metabolite could partially offset the increase in buprenorphine exposure. No evidence for hepatotoxicity was observed in this study, although increased buprenorphine concentrations have been linked to adverse effects in the livers of mice, as a result of impairment of mitochondrial respiration and adenosine triphosphate formation [29] . Long-term use of buprenorphine/naloxone and DLV warrants monitoring of indexes of hepatotoxicity.
The administration of buprenorphine/naloxone in standard clinical dosages had no significant effect on either EFV or DLV concentrations in plasma, either by comparison with historical controls for the former [13] or by empirical observation in the present study for the latter. The data from this study indicate that no adjustment in either of these HIV therapeutics would be required when used for treatment of opioid-dependent, buprenorphine/naloxone-treated patients. The toxicity and efficacy of antiretroviral agents are concerns for HIV clinicians. These findings indicate that changes in drug effects resulting from either subtherapeutic or supratherapeutic concentrations in plasma are unlikely in patients receiving combined treatment with buprenorphine/naloxone and either EFV or DLV.
In summary, EFV decreases buprenorphine exposure but may be administered to buprenorphine-maintained, opioid-dependent individuals without the development of an opioid withdrawal syndrome. DLV administered concomitantly with buprenorphine/naloxone is associated with significant increases in buprenorphine exposure but without opioid toxicity. These findings indicate that buprenorphine/naloxone may be administered in standard clinical dosages effective for the treatment of opioid dependence in combination with these NNRTIs. Thus, in considering opioid therapies for the opioid-dependent patient with HIV disease who may require HAART containing either of these HIV medications, buprenorphine may be preferable to methadone. However, clinical response to the opioid therapy, in terms of its efficacy in the treatment of opioid addiction in individual patients, must be a matter of ongoing clinical review. The lack of adverse drug interactions between buprenorphine and antiretroviral medications will simplify the treatment of both opioid dependence and HIV disease, should findings from this study extend to other HIV medications. This may have the added benefit of increasing adherence to prescribed medication regimens and may contribute to improved clinical outcomes for individuals with these comorbid conditions.
